Combined phacoviscocanalostomy versus phacoemulsification alone in patients with coexisting cataract and mild-to-moderate open-angle glaucoma; a randomized-controlled trial.

BACKGROUND/OBJECTIVE: Management of concomitant cataract and glaucoma depends on the stage of glaucoma and the patient's situation. There are different surgical options for handling visually significant cataract and mild-to-moderate open-angle glaucoma (OAG). We aimed to compare the one-year results of phacoemulsification alone versus phacoviscocanalostomy in these patients. SUBJECTS/METHODS: This was a parallel-arm, single-masked, randomized-controlled trial, conducted at Farabi Eye Hospital, Tehran, Iran between January 2016 and January 2018. We enrolled 89 eyes from 89 patients with mild-to-moderate primary OAG or pseudoexfoliative glaucoma (PEXG) with visually significant age-related cataract. They randomly underwent phacoemulsification alone (n = 44) or combined phaco-viscocanalostomy (n = 45). All patients had a 12-month follow-up period, and the mean intraocular pressure (IOP), the number of antiglaucoma medications, and complete and qualified success rates were compared. RESULTS: After the 1st and 3rd months, the mean IOP showed significantly decreased in the phaco-visco group compared to the phaco group (P < 0001 and P = 0.004, respectively), but it was not statistically significant at 6th and 12th months (P = 0.540 and P = 0.530). The need for antiglaucoma medication and the complete and qualified success rates were significantly in favour of the phaco-visco group in all postoperative visits (P < 0.05). CONCLUSIONS: Although both phacoemulsification alone and phacoviscocanalostomy procedures can be considered for patients with mild-to-moderate OAG, we found better success rates using phacoviscocanalostomy. Therefore, if the surgeon is an expert in performing this technique, this non-penetrating procedure can be applied in patients with visually significant cataract and earlier stages of OAG, especially in patients with PEXG.

Comparing corneal biomechanics and intraocular pressure between healthy individuals and glaucoma subtypes: A cross-sectional study.

Background: The utilization of corneal biomechanical features in evaluating glaucoma and its progression has received particular attention. The severity of corneal biomechanical changes can play an essential role in response to medical or surgical treatment. The present study evaluated the biomechanical features of the cornea in glaucoma patients in different subtypes and compared them with the normal condition. Methods: In this cross-sectional study, glaucoma patients and healthy individuals were referred to the tertiary hospital in 2021. Both eyes underwent a complete ophthalmologic examination, intraocular pressure measurement, and corneal biomechanical parameters using Corvis and ORA devices. Finally, data from both groups were compared. Results: Based on the ORA evaluation, Lower CRF and CH were seen in glaucoma patients. In the Corvis evaluation, minor differences were observed in glaucoma as increased pachy, radius, and pachy slope, and decreased HC deformation amplitude, HC deflection amplitude, HC deflection area, deflection amplitude max, dArc length max, max inverse radius, and integrated radius. Lower ACD and higher CCT differentiated PACG from others. Lower CCT and higher C/D and WTW indicated NTG. Based on ORA, the highest CRF and CH were related to PACG and the lowest related to PEXG. In contrast, based on Corvis, higher pachy and radius and lower max inverse radius and integrated radius were specified for PACG. PEXG also had the highest values of the last two parameters. Conclusion: Evaluation of corneal biomechanical parameters and other indicators can be beneficial in assessing the status and severity of glaucoma and distinguishing between disease subtypes.

Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy.

PURPOSE: To investigate the safety and synergistic effect of topical bevacizumab after trabeculectomy surgery with mitomycin C (MMC). METHODS: In this prospective, non-randomized, comparative interventional study, 40 eyes from 40 patients with uncontrolled open-angle glaucoma were studied after they underwent primary trabeculectomy with mitomycin C (0.02% for 2 min). Following the procedure topical bevacizumab (4 mg/mL) was used for 2 weeks 4 times daily in group A. Patients in group B received routine postoperative care. The outcome measures were the intraocular pressure (IOP), number of anti-glaucoma medications, complications, and bleb evaluation. RESULTS: Of the 32 eyes that had at least 6 months follow-up, 16 were treated with adjuvant topical bevacizumab. The mean preoperative IOP in group A improved from 26.7 ± 9.3 mmHg with 2.8 ± 1.3 anti-glaucoma medications to 10.5 ± 2.8 mmHg with 0.7 ± 1 anti-glaucoma medications at last follow-up (P < 0.001). The mean preoperative IOP in group B improved from 21.8 ± 6.6 mmHg with 3 ± 0.8 anti-glaucoma medications to 11.4 ± 3.6 mmHg with 0.8 ± 1.2 anti-glaucoma medications at last follow-up (P < 0.001). There was an overall reduction of 54.4% and 43.7% in the IOP in groups A and B, respectively (P = 0.18). The cystic type of bleb was less common in group A (P = 0.043). One patient in group A developed a streptococcal corneal ulcer 1.5 months after surgery. CONCLUSION: Administration of topical bevacizumab 4 mg/ml for two weeks following trabeculectomy with mitomycin-C did not significantly affect the IOP trend, but significantly decreased the cystic bleb formation in short-term follow-up.